Form 4 for CRL Charles River Laboratories
Accepted 2025-06-03 00:00:00 ET · period of report 2025-05-30 · accession 0001127602-25-016569 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-06-03 | 2025-05-30 | CRL | Pease Flavia | CFO, Corp. Executive VP | A - Grant | $135.63 | +7,152 | 17.5K | +69% | +$970.0K | |
| 2025-06-03 | 2025-05-31 | CRL | Pease Flavia | CFO, Corp. Executive VP | F - Tax | $135.63 | -185 | 17.3K | -1% | -$25.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-30 | A | A | 7,152 | $135.63 | 17,482 | D | — | — | (F1) Unvested restricted stock units vest annually on: May 30, 2026; May 30, 2027; May 30, 2028; May 30, 2029. |
| 2 | Common | Common Stock | 2025-05-31 | F | D | 185 | $135.63 | 17,297 | D | — | — |